Delaware Chapter of the American College of CardiologyOur purpose is to contribute to the prevention of cardiovascular diseases, to ensure optimal quality of care for individuals with such diseases, and to foster the highest professional ethical standards. Please let us know what information you want to see here. Feel free to contact us with your ideas, needs and comments. |
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- DETECT-HF and BETTER CARE-HF Evaluate Novel HF Alert SystemsTwo presentations at AHA 2026 simultaneously published in JACC: Heart Failure evaluated two novel technologies: a voice-based heart failure (HF) monitoring system, and an EHR-embedded mineralocorticoid receptor antagonists (MRA) prescription prompt.
- OptimPacing: Left Bundle-Branch Pacing vs. Right Ventricular Pacing For Atrioventricular BlockLeft bundle-branch pacing was superior to right ventricular pacing in reducing the risk of death from any cause, heart failure (HF) hospitalization, or pacing-induced cardiomyopathy based on results from the international, multicenter OptimPacing trial, presented at AHA 2026 and simultaneously published in NEJM.
- ADHERE-ASCVD Analysis: Digital Outreach Improves Statin Refills Across Age GroupsDigital outreach through a variety of formats may improve short-term statin refill consistently across a broad age range, according to a prespecified analysis of the ADHERE-ASCVD trial presented at AHA 2026 and simultaneously published in JACC.
- Intensive BP Lowering, Yoga-Based Cardiac Rehab Highlighted Among Late-Breaking Science at AHA 2026Intensive blood-pressure (BP) lowering therapy in patients with type 2 diabetes and a yoga-based cardiac rehabilitation program for people with heart failure and reduced ejection fraction (HFrEF) were among the hot topics in cardiovascular prevention included in a late-breaking clinical science session at AHA 2026.
- STREAM, eZ-PAVE Add New Insights Into Statin Therapy TreatmentDiscontinuing statin therapy in older adults with at least two chronic conditions but no known cardiovascular disease was noninferior to continuation with respect to major cardiovascular events or death from any cause at two years, according to findings from the STREAM trial presented at AHA 2026 and simultaneously published in NEJM.



